PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23151910-1 2013 PURPOSE: To determine the diagnostic efficacy of (11)C-choline PET/CT in patients with prostate cancer (PC) after radical prostatectomy who presented with increasing PSA levels during follow-up in spite of being on hormone treatment (HT), and therefore showing HT resistance. Choline 55-62 aminopeptidase puromycin sensitive Homo sapiens 166-169 23151910-4 2013 (11)C-Choline PET/CT was performed following a standard procedure at our centre to investigate increasing PSA levels, either as the first imaging procedure or in patients with negative conventional imaging. Choline 6-13 aminopeptidase puromycin sensitive Homo sapiens 106-109 18566818-0 2008 [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Choline 5-12 aminopeptidase puromycin sensitive Homo sapiens 90-93 23013665-9 2012 Recent studies indicate that [11C]choline PET/CT has the potential to early restaging PCa patients for PSA levels lower than 1-1.5 ng/mL. Choline 34-41 aminopeptidase puromycin sensitive Homo sapiens 103-106 22220283-6 2011 Choline PET represents the more accurate exam to stage high-risk prostate cancer, and it is useful in staging patients with biochemical relapse, in particular when PSA kinetics is high and/or PSA levels are more than 2 pg/ml. Choline 0-7 aminopeptidase puromycin sensitive Homo sapiens 164-167 22220283-6 2011 Choline PET represents the more accurate exam to stage high-risk prostate cancer, and it is useful in staging patients with biochemical relapse, in particular when PSA kinetics is high and/or PSA levels are more than 2 pg/ml. Choline 0-7 aminopeptidase puromycin sensitive Homo sapiens 192-195 22231016-11 2012 CONCLUSION: Detection rate of (18)F-choline imaging is closely related to PSA and PSA kinetics. Choline 36-43 aminopeptidase puromycin sensitive Homo sapiens 74-77 22231016-11 2012 CONCLUSION: Detection rate of (18)F-choline imaging is closely related to PSA and PSA kinetics. Choline 36-43 aminopeptidase puromycin sensitive Homo sapiens 82-85 22231016-12 2012 In particular, (18)F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt <=6 months and PSAve >2 ng/ml per year. Choline 21-28 aminopeptidase puromycin sensitive Homo sapiens 68-71 19558948-14 2009 (11)C-choline sensitivity was clearly related to PSA levels, was higher in patients with surgery and did not seem to be modified by hormonal therapy. Choline 6-13 aminopeptidase puromycin sensitive Homo sapiens 49-52 17178780-5 2007 The Psa fimbriae bound to PC in a dose-dependent manner, and binding was inhibited by phosphorylcholine (ChoP) and choline. Choline 96-103 aminopeptidase puromycin sensitive Homo sapiens 4-7 24346416-10 2014 In univariate and multivariate analyses PSA kinetics was the only variable affecting (11)C-choline PET/CT detection rate. Choline 91-98 aminopeptidase puromycin sensitive Homo sapiens 40-43 16844733-4 2006 They developed distant metastases which were detected on whole body [C-11] choline positron emission tomography/computed tomography with significant elevation of serum PSA level. Choline 75-82 aminopeptidase puromycin sensitive Homo sapiens 168-171 27277279-14 2016 In patients with a PSA value <1.16 ng/mL, 26.8 % of 1,426 (11)C-choline PET/CT scans were positive, with oligometastatic disease in 84.7 % of positive scans. Choline 67-74 aminopeptidase puromycin sensitive Homo sapiens 19-22 25552670-10 2015 When the GS was greater than 7, the rates of detection of (18)F-choline PET/CT were 51%, 65%, and 91% for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. Choline 64-71 aminopeptidase puromycin sensitive Homo sapiens 108-111